American Journal of Cardiology
Volume 104, Issue 10, Supplement , Pages 3E-9E , 16 November 2009

Low High-Density Lipoprotein Cholesterol and Increased Cardiovascular Disease Risk: An Analysis of Statin Clinical Trials

  • Prakash Deedwania, MD

      Affiliations

    • Veterans Affairs Central California Health Care System/University of California San Francisco, Fresno, California, USA
    • University of California San Francisco School of Medicine, San Francisco, California, USA
    • Corresponding Author InformationAddress for reprints: Prakash Deedwania, MD, Veterans Affairs Central California Health Care System/University of California San Francisco, 2615 East Clinton Avenue, Fresno, California 93703
    • ,
  • Vibhuti Singh, MD

      Affiliations

    • Division of Cardiovascular Disease, Department of Internal Medicine, University of South Florida College of Medicine, St. Petersburg, Florida, USA
    • Suncoast Cardiovascular Center, St. Petersburg, Florida, USA
    • ,
  • Michael H. Davidson, MD

      Affiliations

    • University of Chicago, Pritzker School of Medicine, Chicago, Illinois, USA
    • Radiant Research, Chicago, Illinois, USA

References 

  1. National Cholesterol Education Panel. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report. Circulation. 2002;106:3143–3421
  2. Grundy SM, Cleeman JI, Merz CN, Brewer HB, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110:227–239
  3. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002;287:356–359
  4. Chapman MJ, Assmann G, Fruchart JC, Shepherd J, Sirtori C, for the European Consensus Panel on HDL-C. Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk, the role of nicotinic acid—a position paper developed by the European Consensus Panel on HDL-C. Curr Med Res Opin. 2004;20:1253–1268
  5. Sacks FM Expert Group on HDL Cholesterol. The role of high-density lipoprotein (HDL) cholesterol in the prevention and treatment of coronary heart disease: expert group recommendations. Am J Cardiol. 2002;90:139–143
  6. American Diabetes Association. Dyslipidemia management in adults with diabetes. Diabetes Care. 2004;27(suppl 1):S68–S71
  7. Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD, et al. High-density lipoprotein cholesterol and cardiovascular disease: four prospective American studies. Circulation. 1989;79:8–15
  8. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High-density lipoprotein as a protective factor against coronary heart disease: the Framingham Study. Am J Med. 1977;62:707–714
  9. Stampfer MJ, Sacks FM, Salvin S, Willett WC, Hennekens CH. A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. N Engl J Med. 1991;325:373–381
  10. Goldbourt U, Yaari JS, Medalie JH. Isolated low HDL cholesterol as a risk factor for coronary heart disease mortality: a 21-year follow-up of 8,000 men. Arterioscler Thromb Vasc Biol. 1997;17:107–113
  11. Barter P, Gotto AM, LaRosa JC, Maroni J, Szarek M, Grundy SM, et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med. 2007;357:1301–1310
  12. Lewis GF, Rader JD. New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ Res. 2005;96:1221–1232
  13. Singh IM, Shishehbor MH, Ansell BJ. High-density lipoprotein as a therapeutic target: a systematic review. JAMA. 2007;298:786–798
  14. Barter PJ. Cardioprotective effects of high-density lipoproteins: the evidence strengthens. Arterioscler Thromb Vasc Biol. 2005;25:1305–1306
  15. Mineo C, Deguchi H, Griffin JH, Shaul PW. Endothelial and antithrombotic actions of HDL. Circ Res. 2006;98:1352–1364
  16. Sposito AC, Chapman MJ. Statin therapy in acute coronary syndromes: mechanistic insight into clinical benefit. Arterioscler Thromb Vasc Biol. 2002;22:1524–1534
  17. Gotto AM, Boccuzzi SJ, Cook JR, Alexander CM, Roehm JB, Meyer GS, et al. Effect of lovastatin on cardiovascular resource utilization and costs in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Am J Cardiol. 2000;86:1176–1181
  18. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333:1301–1307
  19. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001–1009
  20. Scandinavian Simvastatin Survival Study Investigators. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383–1389
  21. Chapman MJ. Are the effects of statins on HDL-cholesterol clinically relevant?. Eur Heart J. 2004;6(suppl C):C58–C63
  22. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA. 1998;279:1615–1622
  23. Castelli WP, Garrison RJ, Wilson PWF, Abbott RD, Kalousdian S, Kannel WB. Incidence of coronary heart disease and lipoprotein cholesterol levels: the Framingham Study. JAMA. 1986;256:2835–2838
  24. Lipid Research Clinics Coronary Primary Prevention Trial results (I. Reduction in incidence of coronary heart disease). JAMA. 1984;251:351–364
  25. The Lipid Research Clinics Coronary Primary Prevention Trial results (I. Reduction in incidence of coronary heart disease). JAMA. 1984;251:351–364
  26. Multiple Risk Factor Intervention Trial Research Group. Multiple risk factor intervention trial: risk factor changes and mortality results. JAMA. 1982;248:1465–1477
  27. Assmann G, Schulte H, von Eckardstein A, Huang Y. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk: the PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis. 1996;124(suppl):S11–S20
  28. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomized trials of statins. Lancet. 2005;366:1267–1278
  29. Brown BG, Stukovsky KH, Zhao XQ. Simultaneous low-density lipoprotein-C lowering and high-density lipoprotein-C elevation for optimum cardiovascular disease prevention with various drug classes, and their combinations: a meta-analysis of 23 randomized lipid trials. Curr Opin Lipidol. 2006;17:631–636
  30. Deedwania P, Stone PH, Bairey Merz CN, Cosin-Aguilar J, Koylan N, Luo D, et al Effects of intensive versus moderate lipid-lowering therapy on myocardial ischemia in older patients with coronary heart disease. Circulation. 2007;115:700–707
  31. Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495–1504
  32. LaRosa JC, He J, Vuppiuturi S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA. 1999;282:2340–2346
  33. Deedwania P, Barter P, Carmena R, Fruchart JC, Grundy SM, Haffner S, et al. Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. Lancet. 2006;368:919–928
  34. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7–22
  35. Amarenco P, Labreuche J, Touboul PJ. High-density lipoprotein-cholesterol and risk of stroke and carotid atherosclerosis: a systematic review. Atherosclerosis. 2008;196:489–496
  36. Windler E, Schoffauer M, Zyriax BC. The significance of low HDL-cholesterol levels in an ageing society at increased risk for cardiovascular disease. Diab Vasc Dis Res. 2007;4:136–142
  37. Lipid Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349–1357
  38. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart J-C, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425–1435
  39. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med. 1999;341:410–418
  40. Bezafibrate Infarction Prevention (Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study). Circulation. 2000;102:21–27
  41. Ridker PM, Buring JE, Shih J. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation. 1998;98:731–733
  42. Karthikeyan G, Teo KK, Islam S, McQueen MJ, Pais P, Wang X, et al Lipid profile, plasma apolipoproteins, and risk of a first myocardial infarction among Asians: an analysis from the INTERHEART Study. J Am Coll Cardiol. 2009;53:244–253

 Statement of author disclosure: Please see the Author Disclosures section at the end of this article.

PII: S0002-9149(09)02374-1

doi: 10.1016/j.amjcard.2009.09.013

American Journal of Cardiology
Volume 104, Issue 10, Supplement , Pages 3E-9E , 16 November 2009

Article Tools

* Image Usage & Resolution